Double maintains 1 strategies that include ITOS - iTeos Therapeutics, Inc.
Yahoo
- Multiple TIGIT clinical data readouts anticipated throughout 2025, including >400 patients from two Phase 2 trials and one Phase 1/2 assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - EOS-984 Phase 1 monotherapy and PD-1 combination data anticipated in 2H25 - EOS-215, a potential best-in-class anti-TREM2 monoclonal antibody, IND submission anticipated in 1Q25 - Cash balance and investment balance of $683.9 million as of September 30, 2024 expected to provide runway through 2027 WAT
Yahoo
WATERTOWN, Mass. and GOSSELIES, Belgium, Jan. 08, 2025 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel Detheux, Ph.D., President and Chief Executive Officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on Wednesday, January 15, 2025 at 7:30 AM PST (10:30
Finnhub
iTeos Therapeutics, Inc. dropped from S&P Biotechnology Select Industry Index...
Yahoo
Wells Fargo lowered the firm’s price target on iTeos Therapeutics (ITOS) to $19 from $31 and keeps an Overweight rating on the shares. The firm adjusted price targets in the Smid-cap biotechnology group as part of its 2025 outlook. Wells top sector picks target Ascendis Pharma (ASND), aTyr Pharma (ATYR), Rhythm Pharmaceuticals (RYTM), and Xencor (XNCR). Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See the top stocks recommended b
SeekingAlpha
iTeos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we are bullish on ITOS stock.
Yahoo
iTeos' Phase II trial for inupadenant met its primary and secondary endpoints but offered little more than existing treatments.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
MTD | 49.73% | $28.77B | +12.39% | 0.00% |
NVAX | 48.24% | $1.38B | +127.51% | 0.00% |
GEN | 44.40% | $16.95B | +31.56% | 1.81% |
CDNA | 43.10% | $1.27B | +171.15% | 0.00% |
NNI | 39.42% | $4.09B | +28.11% | 1.00% |
GRVY | 38.63% | $443.90M | -3.09% | 0.00% |
ORGO | 37.93% | $452.61M | +1.12% | 0.00% |
ADMA | 37.90% | $3.99B | +225.68% | 0.00% |
CTLP | 37.30% | $630.60M | +27.81% | 0.00% |
OUST | 37.29% | $511.64M | +108.52% | 0.00% |
SUNS | 35.45% | $81.79M | +4.51% | 5.38% |
ONL | 35.39% | $228.83M | -11.85% | 9.71% |
RCUS | 35.23% | $1.24B | -8.50% | 0.00% |
SG | 34.73% | $3.82B | +195.35% | 0.00% |
MTUS | 34.52% | $644.21M | -25.58% | 0.00% |
BMRN | 34.21% | $12.23B | -28.41% | 0.00% |
IDYA | 32.80% | $2.17B | -42.31% | 0.00% |
TMO | 31.72% | $222.76B | +5.44% | 0.27% |
PLRX | 31.64% | $763.71M | -21.42% | 0.00% |
KELYA | 31.63% | $484.29M | -34.96% | 2.20% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CPRJ | 36.19% | $51.01M | 0.69% |
IBB | 36.02% | $6.48B | 0.45% |
GNOM | 34.80% | $69.52M | 0.5% |
XBI | 34.37% | $6.03B | 0.35% |
IWC | 32.85% | $970.42M | 0.6% |
PBE | 31.88% | $253.29M | 0.58% |
PTH | 31.22% | $126.81M | 0.6% |
ARKG | 31.05% | $1.17B | 0.75% |
FBT | 30.63% | $1.20B | 0.56% |
FIW | 30.39% | $1.81B | 0.53% |
ISCG | 30.27% | $675.05M | 0.06% |
SCHA | 30.16% | $18.77B | 0.04% |
BBH | 30.06% | $397.92M | 0.35% |
KAPR | 29.73% | $163.35M | 0.79% |
VTWO | 29.46% | $11.77B | 0.1% |
ESML | 29.34% | $1.93B | 0.17% |
IWM | 29.24% | $73.84B | 0.19% |
NUSC | 29.22% | $1.26B | 0.31% |
FYX | 29.17% | $968.01M | 0.6% |
KJAN | 29.03% | $353.52M | 0.79% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
FXY | 0.12% | $393.82M | 0.4% |
JPST | 0.13% | $28.94B | 0.18% |
CMDY | 0.18% | $288.98M | 0.28% |
FBY | -0.26% | $182.36M | 0.99% |
TBLL | -0.39% | $2.04B | 0.08% |
IBMN | 0.41% | $473.83M | 0.18% |
MMIN | -0.47% | $485.21M | 0.3% |
BCI | 0.47% | $1.31B | 0.26% |
SHV | 0.48% | $19.24B | 0.15% |
SHYD | -0.49% | $319.74M | 0.35% |
CCOR | 0.72% | $71.67M | 1.18% |
DBB | -0.77% | $109.49M | 0.77% |
BCD | -0.95% | $249.95M | 0.3% |
IBMP | 1.03% | $510.69M | 0.18% |
XHLF | -1.13% | $1.08B | 0.03% |
DUSB | -1.23% | $1.01B | 0.15% |
FXE | 1.26% | $153.26M | 0.4% |
SCHO | 1.26% | $11.41B | 0.03% |
SPYT | -1.30% | $97.70M | 0.94% |
JUCY | 1.30% | $308.94M | 0.6% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
INSM | -0.02% | $14.57B | +180.94% | 0.00% |
VIPS | -0.02% | $6.26B | -14.92% | 2.90% |
ASND | -0.05% | $7.73B | -7.09% | 0.00% |
MAIN | -0.06% | $5.39B | +39.03% | 4.77% |
BP | 0.08% | $82.83B | -12.44% | 5.69% |
VIRT | 0.11% | $3.52B | +151.44% | 2.32% |
IMO | -0.14% | $34.79B | +16.27% | 2.61% |
BRBR | 0.14% | $9.87B | +30.45% | 0.00% |
CMTL | 0.14% | $66.22M | -61.66% | 0.00% |
LPG | -0.16% | $1.06B | -22.03% | 0.00% |
LPLA | 0.17% | $27.44B | +50.32% | 0.32% |
TMUS | -0.18% | $276.79B | +49.85% | 1.16% |
VET | 0.18% | $1.43B | -10.52% | 3.77% |
DXCM | -0.19% | $34.68B | -29.88% | 0.00% |
ECL | -0.19% | $70.71B | +23.01% | 0.95% |
VIV | -0.20% | $14.32B | -14.42% | 0.00% |
FMX | -0.20% | $17.52B | -38.95% | 5.76% |
RNR | -0.22% | $12.15B | -0.23% | 0.66% |
IMRN | 0.23% | $11.91M | +13.97% | 0.00% |
VLO | 0.23% | $44.49B | -0.45% | 3.06% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
FAT | -24.88% | $61.52M | -31.06% | 15.64% |
MGNX | -24.13% | $187.03M | -82.90% | 0.00% |
FATBB | -23.02% | $77.16M | -6.90% | 13.30% |
CME | -21.74% | $87.08B | +17.61% | 4.29% |
OKLO | -19.28% | $6.17B | +375.07% | 0.00% |
CBOE | -13.61% | $21.80B | +12.91% | 1.13% |
AVD | -13.41% | $171.29M | -43.71% | 1.00% |
SVV | -12.67% | $1.79B | -41.52% | 0.00% |
AKAM | -11.81% | $15.16B | -19.65% | 0.00% |
FROG | -11.65% | $4.05B | -0.19% | 0.00% |
XPOF | -11.45% | $566.64M | +68.10% | 0.00% |
SOLV | -10.90% | $12.92B | -6.51% | 0.00% |
MVIS | -10.80% | $344.22M | -35.44% | 0.00% |
SLF | -10.61% | $33.36B | +10.17% | 4.08% |
KRP | -9.49% | $1.41B | +2.52% | 11.25% |
AQB | -8.67% | $2.96M | -68.65% | 0.00% |
TW | -8.39% | $26.68B | +25.87% | 0.31% |
LICY | -8.09% | $30.47M | -72.12% | 0.00% |
CRCT | -7.40% | $1.22B | +18.34% | 3.53% |
MSDL | -7.33% | $1.85B | +3.44% | 9.62% |
Current Value
$7.841 Year Return
Current Value
$7.841 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -18.50% | $270.93M | 1.43% |
VIXY | -17.06% | $195.31M | 0.85% |
UGA | -10.67% | $103.96M | 0.97% |
TAIL | -10.01% | $65.40M | 0.59% |
DBE | -8.95% | $54.84M | 0.77% |
CANE | -8.48% | $13.97M | 0.29% |
OILK | -8.38% | $78.02M | 0.69% |
USL | -8.32% | $48.19M | 0.85% |
BNO | -8.29% | $98.34M | 1% |
UNG | -7.58% | $694.66M | 1.06% |
USO | -7.12% | $1.07B | 0.6% |
COMT | -6.85% | $733.59M | 0.48% |
BSSX | -6.71% | $69.45M | 0.18% |
TPMN | -6.44% | $33.91M | 0.65% |
DBO | -6.26% | $194.96M | 0.77% |
BIL | -6.19% | $36.90B | 0.1356% |
KRBN | -5.91% | $198.18M | 0.85% |
GSG | -5.17% | $1.06B | 0.75% |
PDBC | -4.87% | $4.40B | 0.59% |
BILS | -4.75% | $3.34B | 0.1356% |